May 6th 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Overall Survival Approaching 5 Years for Metastatic Renal Cell Carcinoma
February 9th 2022In an interview with Targeted Oncology, James Brugarolas, MD, PhD discussed promising updated survival data in metastatic renal cell carcinoma and investigational biomarkers to further advanced the field.
Read More
Roundtable Discussion: Integrating New Approaches for Advanced Relapsed/Refractory RCC Into Practice
January 28th 2022During a Targeted Oncology case-based roundtable event, Sumanta Kumar Pal, David I. Quinn, MD, MBBS, PhD, and participants discussed frontline therapy options for a patient with metastatic relapsed/refractory renal cell carcinoma.
Read More
Does the Addition of Cabozantinib to Atezolizumab Improve Survival in Advanced RCC?
January 11th 2022The target number of patients with advanced renal cell carcinoma has been enrolled in the phase 3 CONTACT-3 trial, which aims to determine the efficacy and safety of cabozantinib combined with atezolizumab.
Read More
Part 2: Tolerability of Immunotherapy plus TKI Inhibitors in RCC
December 27th 2021During a live virtual event, Sandy Srinivas, MD, discussed the tolerability of the tyrosine kinase inhibitor/immunotherapy combinations cabozantinib plus nivolumab and lenvatinib plus pembrolizumab, compared with the dual immunotherapy ipilimumab plus nivolumab.
Read More
Select Kidney Tumors With Sarcomatoid Dedifferentiated RCC Still Challenging to Treat
December 27th 2021In an interview with Targeted Oncology, Matthew T. Campbell, MD, discussed unmet needs for patients with renal cell carcinoma and sarcomatoid dedifferentiation. He also explained how to approach the treatment of patients with challenging non-clear cell tumors.
Read More
Managing Adverse Reactions in Patients With RCC Treated With Lenvatinib/Pembrolizumab
December 21st 2021Proactive management of treatment-emergent adverse events, including treatment interruption, may be crucial for patients with renal cell carcinoma receiving lenvatinib in combination with pembrolizumab, according to the CLEAR study investigators.
Read More
Part 1: Real-World Experience With Dosing Lenvatinib/Pembrolizumab in RCC
December 20th 2021During a live virtual event, Sandy Srinivas, MD, discussed results from the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and the participants' experiences with the regimen including dose reductions needed by their patients across multiple cancer types.
Read More
Roundtable Discussion: Rini Reviews Later-Line Immunotherapy and TKI Combinations in Refractory RCC
December 2nd 2021Based on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.
Read More